Stockscreener 앱 받기
111.94
0.01%
-0.01
전일 마감가:
$111.95
열려 있는:
$112.88
하루 거래량:
4.43M
Relative Volume:
1.06
시가총액:
$498.76B
수익:
$37.42B
순이익/손실:
$13.05B
주가수익비율:
46.49
EPS:
2.4077
순현금흐름:
$9.51B
1주 성능:
-1.27%
1개월 성능:
-5.14%
6개월 성능:
-13.37%
1년 성능:
+14.60%
1일 변동 폭
$111.79
$113.02
1주일 범위
$107.24
$113.76
52주 변동 폭
$94.73
$148.15
노보 노디스크 Stock (NVO) Company Profile
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today? - Benzinga
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
Why this money manager sees FirstService, Novo Nordisk and Microsoft as good long-term holdings - The Globe and Mail
NVO: 3 European Stocks to Buy as the Region Recovers - StockNews.com
NVO’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News
Market cap of Novo Nordisk ADR [NVO] reaches 391.26B – now what? - The DBT News
Analyzing Novo Nordisk ADR (NVO) After Recent Trading Activity - Knox Daily
Monitoring Melco Resorts & Entertainment Ltd ADR (MLCO) after recent insider movements - Knox Daily
Weekly Upgrades and Downgrades - InvestorPlace
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
Novo Nordisk Currently Down Six Consecutive Days, on Pace for Longest Losing Streak Since September 2022 — Data Talk - Morningstar
Novo Nordisk ADR (NVO) receives a Buy rating from Goldman - Knox Daily
The Attractiveness of Investing In Tenaris S.A. ADR (TS) is Growing - Knox Daily
Stock Market Recap: Novo Nordisk ADR (NVO) Concludes at 118.01, a -0.89 Surge/Decline - The Dwinnex
Banco Santander S.A. ADR [SAN] Investment Appeal on the Rise - Knox Daily
Analyzing Indonesia Energy Corp Ltd (INDO) After Recent Trading Activity - Knox Daily
CNH Industrial NV [CNH] Investment Guide: What You Need to Know - Knox Daily
Company’s Banking Stock: Dissecting a -17.46% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Novo Nordisk ADR (NVO) Stock: A Year of Decreases and Increases - The InvestChronicle
Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales - Investor's Business Daily
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk? - Morningstar
Eli Lilly Stock: Is LLY Stock A Buy After Snagging Approval For A New Eczema Drug? - Investor's Business Daily
Analysts review Novo Nordisk ADR’s rating - Knox Daily
Wall Street Analyst Initiated Novo Nordisk ADR [NVO]. What else is Wall St. saying - The DBT News
Novo Nordisk A/S ADR (NVO-N) QuotePress Release - The Globe and Mail
Balance Sheet Insights: Novo Nordisk ADR (NVO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Novo Nordisk ADR (NVO) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
European Equities Traded in the US as American Depositary Receipts Decrease Friday - MSN
Novo Dives — And Corbus Crashes — On Psychiatric Side Effects Of Weight-Loss Drug - Investor's Business Daily
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.16%
0.17%
자본화:
|
볼륨(24시간):